Is EBS or EDSA more undervalued in 2026?

CirclFi compares Emergent BioSolutions Inc. (EBS) and Edesa Biotech, Inc. (EDSA) using 13 institutional-grade valuation models. EBS has a Quality of Company score of 8.3/10 while EDSA scores 3.9/10.

Which is a better buy — EBS or EDSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EBS and EDSA valuations compare?

EBS at $9.12 and EDSA at $7.22 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EBS vs EDSA Valuation Comparison 2026 — Intrinsic Value Analysis

EBS

Pharmaceutical Preparations

Emergent BioSolutions Inc.

Quality

8.3

out of 10

Value Trap

SAFE

Price

$9.12

Last close

Models

12/13

Active

EDSA

Pharmaceutical Preparations

Edesa Biotech, Inc.

Quality

3.9

out of 10

Value Trap

SAFE

Price

$7.22

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	EBS Fair Value	EBS Upside	EDSA Fair Value	EDSA Upside
Bayesian DCF	Intrinsic	$27.60	+202.6%	$3.47	-51.9%
Earnings Power Value	Intrinsic	$52.15	+471.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$17.76	+94.8%	$0.65	-91.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EBS vs EDSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EBS vs EDSA — Which Stock Is More Undervalued?

EBS scores higher with a 8.3/10 quality rating vs EDSA's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Emergent BioSolutions Inc. (EBS) and Edesa Biotech, Inc. (EDSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EBS currently trades at $9.12 with a QOC of 8.3/10, while EDSA trades at $7.22 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).